Uses and Administration Adverse Effects and Precautions Pharmacokinetics Uses and Administration

Total Page:16

File Type:pdf, Size:1020Kb

Uses and Administration Adverse Effects and Precautions Pharmacokinetics Uses and Administration 1549 The adverse effects of dicobalt edetate are more severe in year-old child: case report and review of literature. Z Kardiol 2005; 94: References. 817-2 3. the absence of cyanide. Therefore, dicobalt edetate should I. Schaumann W, et a!. Kinetics of the Fab fragments of digoxin antibodies and of bound digoxin in patients with severe digoxin intoxication. Eur 1 not be given unless cyanide poisoning is confirmed and 30: Administration in renal impairment. In renal impairment, Clin Pharmacol 1986; 527-33. poisoning is severe such as when consciousness is impaired. 2. Ujhelyi MR, Robert S. Pharmacokinetic aspects of digoxin-specific Fab elimination of antibody-bound digoxin or digitoxin is therapy in the management of digitalis toxicity. Clin Pharmacokinet 1995; Oedema. A patient with cyanide toxicity developed delayed1·3 and antibody fragments can be detected in the 28: 483-93. plasma for 2 to 3 weeks after treatment.1 The rebound in 3. Renard C, et al. Pharmacokinetics of dig,'><i<1-sp,eei1ie Fab: effects of severe facial and pulmonary oedema after treatment with decreased renal function and age. 1997; 44: 135-8. dicobalt edetate.1 It has been suggested that when dicobalt free-digoxin concentrations that has been reported after edetate is used, facilities for intubation and resuscitation treatment with digoxin-specific antibody fragments (see P (Jrations should be immediately available. Poisoning, below), occurred much later in patients with r.�p renal impairment than in those with normal renal func­ Proprietary Preparations (details are given in Volume B) 1. Dodds C, McKnight C. Cyanide toxicity after immersion and the hazards tion. Those with severe renal impairment may need to be of dicobalt edetate. BMJ 1985; 291: 785-6. Single�ingredient Preparations. Austral.: Digibind; Canad.: observed for longer after treatment with antibody frag­ Digibindt; DigiFab; Fr.: Digibindt; Gr.: Digibind; DigiFab; Hong ments, and monitoring of free (unbound) plasma-digoxin Kong: Digitalis Antidote; UK: Digibind; DigiFab; USA: concentrations may be useful.1 Digibindt; DigiFab. Proprietary Preparations (details are given in Volume B) l. Flanagan RJ, Jones AL. Fab antibody fragments: some applications in clinical toxicology. 27: 1115-33. Single-ingredient Preparations. Fr.: Kelocyanor; 2. Al.len NM, et al. and pharmacokinetic profiles of digoxin Kelocyanor. immune Fab in four patients with renal impairment. DICP Ann Dimercaprol /BAN, riNN! Pharmacother 1991; 25: l315-20. 3. Ujhelyi MR, et al. Disposition of digoxin immune Fab in patients with BAL; f:lritis!1 Antl'LE;>y isite; Dirileitapro!um; Dim10rkaprol; kidney failure. Clin Pharmacal Ther 1993; 54: 388-94. Dimerk<jproH; Dimerkaproiis;).]I'IMepK<>nponc Digoxin-specific Antibody 23-Dimercaptopropan, 1-oi. Poisoning. Digoxin-specific antibody fragments can (\H50S2�124.2 Fragments reverse severe digitalis toxicity with an initial response · CA s � $:9-52-9. Digoxin tmmune F,ab (Ovine); .·· P(ab); Fragrr,entos usually seen within 30 minutes of the end of the infusion. licuerpos · · Fab Haemodynamic status normally improves, but in those ATC -'-- V03A B09. aQ e�p£:ch1cos . antidtgoxin�;. Fragmentos . antic\]e;rpos·antldigoxlna; .AHTV<AVI(OKG1H. with heart failure withdrawal of the inotropic support pro­ ATCVet."--- QV03A!309. UNi! ·.,-" OCPP32555X ATC-VOJABN vided by digoxin may produce a decline in cardiac func­ tion. Plasma potassium concentrations may fall rapidly Pharmacopoeias. In Chin., Bur. (see p. vii), Int., Jpn, US, and AtCV<?t � QV03AB24. after reversal of toxicity. Glycoside toxicity has been UNI/ Viet. �.YBI2NQZ IYN. reported to recur within 24 hours after treatment with Ph. Eur. 8; (Dimercaprol). A clear colourless or slightly antibody fragments. The reason for this is unclear, yellow liquid. Soluble in water and in arachis oil; miscible although it has been suggested that changes in the distri· Uses and Administration with alcohol and with benzyl benzoate. Store at 2 degrees to bution of glycoside and antibody fragments may play a Digoxin-specific antibody fragments are derived from 8 degrees in well-filled airtight containers. Protect from role.u It has been suggested that for either acute or antibodies produced in sheep immunised to digoxin. light. chronic toxicity, half the calculated loading dose (see Uses Digoxin has greater affinity for the antibodies than for and Administration, above) should be given initially, with USP 36; (Dimercaprol). A colourless or practically colourless tissue-binding sites, and the digoxin-antibody complex is further doses given only if response is inadequate or if liquid, having a disagreeable, mercaptan-like odour. Soluble then excreted in the urine. Digoxin-specific antibody toxicity recurs.3 Digoxin-specific antibody fragments are 1 in 20 of water; soluble in alcohol. in benzyl benzoate, and fragments are used to treat severe digoxin or digitoxin usually reserved for severe or life-threatening digitalis in methyl alcohol. Store at a temperature not exceeding 8 intoxication (p. 1355.1) in which conventional treatment is toxicity, such as that associated with significant hyperkal­ degrees in airtight containers. Protect from light. ineffective. Successful treatment of lanatoside C poisoning aemia, arrhythmias, or bradycardia;3 however they have has also been reported. also been used in patients with less severe toxicity but It is estimated that 38 or 40 mg (depending on the Uses and Administration vvith poor prognostic features such as underlying cardiac preparation) of antibody fragments can bind about Dimercaprol is a chelator that has been used in the disease or age over 55 years.4 500 micrograms of digoxin or digitoxin; the dose is thus treatment of acute poisoning by arsenic (p. 2449.1), gold Digoxin-specific antibody fragments have also been used calculated using the steady-state plasma concentration or (p. 131.3), and mercury (p. 2556.3). It may also be used in to reverse toxicity from cardiac glycosides present in other the amount of glycoside ingested. Doses are diluted in the treatment of poisoning by other heavy metals such as plants such as common or yellow oleander (p. 2574.3) and sodium chloride 0. 9% and given by intravenous infusion antimony and bismuth, and, with sodium calcium edetate, in poisoning due to preparations containing toad venom.5 over 30 minutes via a 0.22-micrometre in-line filter. If in acute lead poisoning (p. 2542.1). However, other I. Ujhelyi MR, Robert S. Pbarmacokinetk aspects of digoxin-specific Fab cardiac arrest is imminent the dose may be given as a bolus. chelators may be preferred for systemic use. Djmercaprol therapy in the management of digitalis toxicity. Clin Pharmacokinet 1995; In the case of incomplete reversal or recurrence of toxicity a 28: 483-93. has been used in refractory Wilson's disease (p. 1567.3). further dose can be given after several hours. 2. Flanagan RJ, Jones AL. Fab antibody fragments: some applications in Dimercaprol 5% has been applied as an ointment for skin After acute ingestion of an unknown amount of digoxin clinical toxicology. Drug Safety 2004; 27: 1115-3 3. lesions or as eye drops for ocular symptoms of arsenic 3. Bateman ON. Digoxin-specific antibody fragments: how much and or digitoxin a dose of 760 or 800 mg is suggested; toxicity. when? Toxicol Rev 2004; 23: 135-43. alternatively an initial dose of 380 or 400 mg can be given 4. Lapostolle F, et al. Digoxin-specific Fab fragments as single first-line The sulfhydryl groups on dimercaprol compete with with an additional 380 or 400 mg if required. For toxicity therapy in digitalis poisoning. Crit Care Med 2008; 36: 3014-18. endogenous sulfhydryl groups on proteins such as enzymes during chronic therapy when the steady-state plasma 5. Brubacher JR, et at. Treatment of toad venom poisoning with digoxin­ to combine with these metals; chelation by dimercaprol specific Fab fragments. Chest 1996; llO: 1282-8. concentration is unknown, a dose of 228 or 240 mg is therefore prevents or reverses any inhibition of the suggested. sulfhydryl enzymes by the metal and the dimercaprol-metal For doses in children, see Administration in Children, Adverse Effects and Precautions complex formed is readily excreted by the kidney. Since the below. complex may dissociate, particularly at acid pH, or be Allergic reactions to digoxin-specific antibody fragments Digoxin-specific antibody fragments are being investi­ oxidised, the aim of treatment is to provide an excess of have been reported rarely. A pruritic rash, facial flushing gated for the treatment of hypertension, particularly in dimercaprol in body fluids until the excretion of the metal is and swelling, and chills in the absence of fever have eclampsia and pre-eclampsia. complete. occurred on the day of treatment, and urticaria and Dimercaprol should be given by deep intramuscular thrombocytopenia have been reported up to 16 days after It has been suggested' that giving injection in the treatment of heavy metal poisoning. The Administration. treatment. digoxin-specific antibody fragments by infusion over 7 individual dose is determined by severity of symptoms and Patients known to be allergic to sheep protein and those hours, after an initial loading dose, could be useful in the causative agent. Single doses should not generally previously given digoxin-specific antibody fragments may ensuring adequate antibody concentrations are main­ exceed 3 mg/kg but single doses of up to 5 mg/kg may be be at greater risk of developing an allergic reaction. An tained to bind digoxin as it is released from tissue stores required initially in patients with severe acute poisoning. intradermal or skin scratch test may be used to test for over a prolonged period. Various dosage schedules are in use. sensitivity in those considered to be at high risk. In the UK, 400 to 800 mg is given on the first day of I. Schaumann W, ct al. Kinetics of the Fab fragmenb of digoxin antibodies Blood pressure, ECG, and potassium concentrations and of bound digoxin in patients wiTh severe digoxin intoxic<�tion.
Recommended publications
  • Review of Succimer for Treatment of Lead Poisoning
    Review of Succimer for treatment of lead poisoning Glyn N Volans MD, BSc, FRCP. Department of Clinical Pharmacology, School of Medicine at Guy's, King's College & St Thomas' Hospitals, St Thomas' Hospital, London, UK Lakshman Karalliedde MB BS, DA, FRCA Consultant Medical Toxicologist, CHaPD (London), Health Protection Agency UK, Visiting Senior Lecturer, Division of Public Health Sciences, King's College Medical School, King's College , London Senior Research Collaborator, South Asian Clinical Toxicology Research Collaboration, Faculty of Medicine, Peradeniya, Sri Lanka. Heather M Wiseman BSc MSc Medical Toxicology Information Services, Guy’s and St Thomas’ NHS Foundation Trust, London SE1 9RT, UK. Contact details: Heather Wiseman Medical Toxicology Information Services Guy’s & St Thomas’ NHS Foundation Trust Mary Sheridan House Guy’s Hospital Great Maze Pond London SE1 9RT Tel 020 7188 7188 extn 51699 or 020 7188 0600 (admin office) Date 10th March 2010 succimer V 29 Nov 10.doc last saved: 29-Nov-10 11:30 Page 1 of 50 CONTENTS 1 Summary 2. Name of the focal point in WHO submitting or supporting the application 3. Name of the organization(s) consulted and/or supporting the application 4. International Nonproprietary Name (INN, generic name) of the medicine 5. Formulation proposed for inclusion 6. International availability 7. Whether listing is requested as an individual medicine or as an example of a therapeutic group 8. Public health relevance 8.1 Epidemiological information on burden of disease due to lead poisoning 8.2 Assessment of current use 8.2.1 Treatment of children with lead poisoning 8.2.2 Other indications 9.
    [Show full text]
  • Sodium Cellulose Phosphate Sodium Edetate
    Sevelamer/Sodium Edetate 1463 excreted by the kidneys. It may be used as a diagnostic is not less than 9.5% and not more than 13.0%, all calculated on supplement should not be given simultaneously with test for lead poisoning but measurement of blood-lead the dried basis. The calcium binding capacity, calculated on the sodium cellulose phosphate. dried basis, is not less than 1.8 mmol per g. concentrations is generally preferred. Sodium cellulose phosphate has also been used for the Sodium calcium edetate is also a chelator of other Adverse Effects and Precautions investigation of calcium absorption. heavy-metal polyvalent ions, including chromium. A Diarrhoea and other gastrointestinal disturbances have Preparations cream containing sodium calcium edetate 10% has been reported. USP 31: Cellulose Sodium Phosphate for Oral Suspension. been used in the treatment of chrome ulcers and skin Sodium cellulose phosphate should not be given to pa- Proprietary Preparations (details are given in Part 3) sensitivity reactions due to contact with heavy metals. tients with primary or secondary hyperparathyroidism, Spain: Anacalcit; USA: Calcibind. Sodium calcium edetate is also used as a pharmaceuti- hypomagnesaemia, hypocalcaemia, bone disease, or cal excipient and as a food additive. enteric hyperoxaluria. It should be used cautiously in pregnant women and children, since they have high Sodium Edetate In the treatment of lead poisoning, sodium calcium calcium requirements. Sodu edetynian. edetate may be given by intramuscular injection or by Patients should be monitored for electrolyte distur- intravenous infusion. The intramuscular route may be Эдетат Натрия bances. Uptake of sodium and phosphate may increase CAS — 17421-79-3 (monosodium edetate).
    [Show full text]
  • PHARMACOLGY HOMEWORK Overdose Management Add In
    PHARMACOLGY HOMEWORK Overdose Management Add in important nursing notes for each of these medications and overdose management as well as administration route. Medication Overdose Nursing Notes (*Homework) Management (Routes) Acetaminophen Acetylcysteine Acetaminophen: (PO/PR) Route: PO, IV Max daily dose: 4000mg Acute toxicity (overdose) Monitor for S+S of hepatotoxicity (éLFTs, bilirubin, hypoglycemia, renal damage) Acetylcysteine: IV infusion: monitor for fluid overload and signs of hyponatremia such as changes in mental status Monitor for S+S of aspiration, bronchospasm, excess secretions Digitalis Digoxin Immune Fab Digoxin: (PO/IV) (Ovine, Digibind) Take apical pulse for 60sec. If < 60 BPM hold Route: IV digoxin dose and contact prescriber. Monitor serum digoxin (it has a narrow therapeutic index), potassium, magnesium, calcium. Monitor for S+S toxicity: anorexia, nausea, vomiting, diarrhea, visual disturbances, cardiac arrhythmias Digoxin Immune Fab: Skin allergy testing prior to administration for history of allergy or previous therapy of this drug Monitor cardiac status + rhythm, neurological status Toxicity reversal within an hour (adults), minutes (children) of antidote administration Monitor serum potassium, critical within first few hours; serum digoxin levels, ECG for 2-3 weeks post administration Heparin Protamine sulfate Heparin: (IV/SC) (IV) Monitor for spontaneous bleeding, thrombocytopenia Monitor aPTT levels Protamine Sulfate: Sudden drop in BP Monitor BP+ P q15-30 min Monitor aPTT Opioid Naloxone (IV-adults, Opioids:
    [Show full text]
  • Product Information
    PRODUCT INFORMATION DIGIFAB®1 POWDER FOR INJECTION (DIGOXIN-SPECIFIC ANTIBODY FRAGMENT F(Ab) (OVINE)) 1 NAME OF THE MEDICINE Digoxin-specific antibody fragment F(Ab) (Ovine) 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial of DIGIFAB Powder for Injection, will bind approximately 0.5 mg digoxin, contains 40 mg of digoxin- specific antibody fragment F(Ab). These fragments are obtained from blood of healthy sheep immunized with a digoxin derivative, digoxin- dicarboxymethoxylamine (DDMA), a digoxin analogue which contains the functionally essential cyclopentaperhydrophenanthrene:lactone ring moiety coupled to keyhole limpet hemocyanin (KLH). The final product is prepared by isolating the immunoglobulin fraction of the ovine serum, digesting it with papain and isolating the digoxin-specific Fab fragments by affinity chromatography. For the full list of excipients, see Section 6.1 List of Excipients. 3 PHARMACEUTICAL FORM DIGIFAB, digoxin-specific antibody fragment F(Ab) (Ovine) Powder for Injection, is a sterile, purified, lyophilized off-white powder of digoxin-specific antibody ovine Fab (monovalent) immunoglobulin fragments. The pH of the reconstituted solution is in between 4.5-5.5. The product is intended for intravenous administration after reconstitution with 4 mL of Sterile Water for Injection. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Digoxin-specific antibody fragment F(Ab) (Ovine) DIGIFAB is indicated for the treatment of known (or strongly suspected) life-threatening digoxin toxicity associated with ventricular arrhythmias, progressive bradycardia, or second or third degree heart block not responsive to atropine, and where additional measures besides withdrawal of digoxin and correction of serum electrolyte abnormalities are considered necessary. Consequences of multiple dosing with DIGIFAB have not been evaluated.
    [Show full text]
  • Antidote List
    Antidote List Recommended minimum amounts for hospital pharmacies to stock Call the Maryland Poison Center for expert advice on the treatment of all poisonings and overdoses: 1-800-222-1222 Poisoning Minimum Stocking Antidote Indication Recommendations Oral: 120 grams Acetylcysteine Acetaminophen IV: 96 grams Crotaline snake Antivenin, snake (CroFab®) 12 vials envenomation 1 vial Black widow spider (Note: Merck limits distribution Antivenin, black widow spider envenomation to cases of confirmed bites with symptoms only) Organophosphate & Atropine carbamate insecticides, nerve 165 mg gases Calcium chloride Calcium channel blockers 10 grams 2.25 grams Calcium disodium EDTA Lead (Available direct from ASD Specialty Healthcare) Hydrofluoric acid 1 kg (powder) Calcium gluconate Calcium channel blockers IV: 30 grams 1 kit Cyanide Antidote Kit Cyanide (or Hydroxocobalamin, see below) Cyproheptadine (Periactin®) Serotonin syndrome 80 mg Neuroleptic malignant Dantrolene syndrome, stimulant-induced 720 mg hyperthermia Deferoxamine mesylate Iron 8 grams (Desferal®) Digoxin Immune FAB Digoxin 20 vials (Digibind®, DigiFab®) Dimercaprol (BAL) Heavy metals 1.5 grams 1 | P a g e Maryland Poison Center Antidote List – continued Poisoning Minimum Stocking Antidote Indication Recommendations DMSA (Succimer, Chemet®) Heavy metals 2000 mg Folic acid Methanol IV: 150 mg Flumazenil (Romazicon®) Benzodiazepines 10 mg Fomepizole (Antizol®) Ethylene glycol, methanol 12 grams Beta blockers, Glucagon 50 mg calcium channel blockers Hydroxocobalamin (Cyanokit®) Cyanide
    [Show full text]
  • Nova Scotia Antidote Program 2021 Quarterly Report #1 Jan 1, 2021 to Mar 31, 2021
    Nova Scotia Antidote Program 2021 Quarterly Report #1 Jan 1, 2021 to Mar 31, 2021 The Nova Scotia Antidote Program is pleased to present another Quarterly Report, which provides information on changes and trends in antidote therapy and reports ongoing Provincial Antidote usage. Antidote usage Jan 1 to Mar 31, 2021 Western Northern Eastern Central IWK Quarterly Year to Date Zone Zone Zone Zone Total 6 7 7 20 2 42 42 Highlights of antidote use during the past 3 months A total of 42 antidotes were used in 32 different patient cases. Of these, 4 antidotes were used by community hospitals, 29 in regional facilities and 9 in tertiary hospitals. • Antidotes accessed in community hospitals: naloxone and sodium bicarbonate • Sodium Bicarbonate was used in six patients: Three patients with salicylate toxicity and three patients with evidence of sodium channel blockade (wide QRS). • Naloxone was reported as used for 18 patients with known or suspected opioid toxicity. o Six of these patients required a naloxone infusion, along with bolus dose(s). ISMP Alert: Methylene Blue The Institute for Safe Medication Practices Canada (ISMP) has issued a statement about “Hospital Readiness to Use the Antidote Methylene Blue”. There have been reported emergency situations where there was confusion as to the availability and dosing of methylene blue, resulting in delays in administration. (ISMP Canada Safety Bulletin; Vol. 21, Issue 5; May 6, 2021) Through our Provincial Antidote Program, emergency departments across Nova Scotia have sufficient stock (10 vials in Regional Kits, 3 vials in Community Kits) and access to online antidote monographs with information about methylene blue dosing and administration, adverse effects and monitoring parameters.
    [Show full text]
  • Antidote Stocking Tier C
    These Tier C recommendations are general To Contact your Regional Poison Center: (800) 222-1222 Consultation is available by a Specialist in Poison Information or Toxicologist (upon request) 24 hours daily. Toxin Current Recommended Antidote Dosing Other Info Stock Stock Indicated for moderate to severe envenomations Moderate: Evidence of local tissue injury that extends 1 4-6 vials IV q2-4h Antivenin Snake bite major joint proximal to bite until pain improves, Crotalidae (Copperhead, and/or numeric coagulopathy 12 vials swelling stops, or Polyvalent Immune Water without clinical bleeding clinical bleeding FAB moccasins, resolves, then 2 vials (CroFab™) Rattlesnakes) Severe: Local injury >1 joint, q6h for 3 doses documented compartment syndrome, coagulopathy with clinical bleeding, hypotension, angioedema, and/or neurological findings None (currently must be drop-shipped based Antivenin-black Black Widow 1 vial in 50 ml of NS Equine derived antivenom on patient presentation widow envenomation – black widows not likely in western KY) Organo- 2-4 mg IV q5-10 phosphate or minutes or 0.02- carbamate Indicated for SLUDGE 5 x 20 ml (0.4 mg/ml) 0.08 mg/kg/hr IV Atropine pesticides symptoms associated with vials infusion until and cholinergic excess excessive bronchial muscarine secretions terminate mushrooms These Tier C recommendations are general To Contact your Regional Poison Center: (800) 222-1222 Consultation is available by a Specialist in Poison Information or Toxicologist (upon request) 24 hours daily. Antidote Current Recommended Toxin
    [Show full text]
  • An Oral Treatment for Lead Toxicity Paul S
    Postgrad Med J: first published as 10.1136/pgmj.67.783.63 on 1 January 1991. Downloaded from Postgrad MedJ (1991) 67, 63 - 65 D The Fellowship ofPostgraduate Medicine, 1991 Clinical Toxicology An oral treatment for lead toxicity Paul S. Thomas' and Charles Ashton2 'Northwick Park Hospital, Harrow, Middlesex HA] 3UJand2National Poisons Unit, Guy's Hospital, London SE], UK. Summary: Chronic lead poisoning has traditionally been treated by parenteral agents. We present a case where a comparison of ethylene diaminetetra-acetic acid was made with 2,3-dimethyl succinic acid (DMSA) which has the advantage oforal administration associated with little toxicity and appeared to be at least as efficacious. Introduction For many years the treatment of heavy metal ferase 112IU/I (normal<40). His electrolytes, poisoning has relied upon parenteral agents which urea, creatinine, clotting screening chest radio- themselves have a number of toxic side effects. We graph, computed tomographic head scan and lum- report a case ofplumbism which shows the benefits bar puncture were all normal. of using 2,3-dimethyl succinic acid (DMSA), a Re-evaluation revealed lead lines on his gingival treatment relatively new to Western countries. In margins and a urinary porphyrin screen was posi- by copyright. our case it was used in direct comparison to the tive indicating lead toxicity. Despite careful social, sodium-calcium salt of ethylene diaminetetra- occupational, and recreational history no cause for acetic acid, which has been the best available his excess lead intake could be found. As he was treatment. domiciled in India it was not possible to visit his home or workplace where he sold sarees.
    [Show full text]
  • Antidote Stocking Tier A
    These Tier A recommendations are general To Contact your Regional Poison Center: (800) 222-1222 Consultation is available by a Specialist in Poison Information or Toxicologist (upon request) 24 hours daily. Toxin Current Recommended Antidote Dosing Other Info Stock Stock Indicated for moderate to severe envenomations Moderate: Evidence of local tissue injury that extends 1 4-6 vials IV q2-4h Antivenin Snake bite major joint proximal to bite until pain improves, Crotalidae (Copperhead, and/or numeric coagulopathy 24 vials swelling stops, or Polyvalent Immune Water without clinical bleeding clinical bleeding FAB moccasins, resolves, then 2 vials (CroFab™) Rattlesnakes) Severe: Local injury >1 joint, q6h for 3 doses documented compartment syndrome, coagulopathy with clinical bleeding, hypotension, angioedema, and/or neurological findings None (currently must be drop-shipped based Antivenin-black Black Widow 1 vial in 50 ml of NS Equine derived antivenom on patient presentation widow envenomation – black widows not likely in western KY) Organo- 2-4 mg IV q5-10 phosphate or minutes or 0.02- carbamate Indicated for SLUDGE 30 x 20 ml (0.4 mg/ml) 0.08 mg/kg/hr IV Atropine pesticides symptoms associated with vials infusion until and cholinergic excess excessive bronchial muscarine secretions terminate mushrooms These Tier A recommendations are general To Contact your Regional Poison Center: (800) 222-1222 Consultation is available by a Specialist in Poison Information or Toxicologist (upon request) 24 hours daily. Antidote Current Recommended
    [Show full text]
  • Antidotes Atropine Calcium
    Version 2.9 Antidotes 4/10/2013 Atropine Indications AV conduction impairment: Cardiac glycosides , β-blockers , calcium channel blockers (CCBs) . Anticholinesterase inhibitors/Cholinergics: Organophosphates, carbamates Contraindications Relative: closed angle glaucoma, GIT obstruction, urinary obstruction Mechanism Competitive antagonist for ACh at muscarinic receptors. Pharmacokinetics Poor oral bioavailability, liver met, T ½=2-4hrs. Crosses BBB & placenta. 50% excreted unaltered. Administration AV conduction impairment: 0.6mg (20mcg/kg) IV repeated up to 3x Cholinergics: 1.2mg IV bolus, double dose q5mins until chest clear [also sBP>80mmHg, HR>80, dry axillae & no miosis]. Then infusion starting at ~10-20% of total loading dose (max 35mg/hr) Adverse Reactions Excessive dosage → Anticholinergic toxidrome. Calcium Indications CCB OD, HF exposure, hypocalcaemia, hyperkalaemia, iatrogenic hypermagnesaemia Contraindications Hypercalcaemia, ?digoxin toxicity - (contrary to traditional teaching, recently some evidence 2+ that Ca is not CI if on digoxin or even if digoxin toxic – however digoxin immune Fab & MgSO 4 10mmol might be preferred initially in the latter case) Mechanisms Restore low Ca2 + levels, binds F- ions, antagonises effects of high K + & Mg 2+ on heart. Administration Cardiac monitoring mandatory. CCBs: 20ml CaCl 2 IV (central line) or 60ml (1ml/kg) Ca gluconate IV (peripheral) over 5-10mins HF on skin: 2.5% Ca gel TOP OR local inj of 10% calcium gluconate (not fingers) OR Bier’s block with 2% Ca gluconate (i.e. 10ml of 10% in 40ml NS) for 20mins & release cuff OR same dose intra-arterially over 4 hrs & rpt prn. HF inhaled: Nebulised 2.5% Ca gluconate solution. HypoCa/HypoMg/HyperK: 5-10ml CaCl 2 or 10-20ml (1ml/kg) Ca gluconate IV over 5-10mins Adverse Reactions Transient hyperCa., vasodilatation, hypoBP, dysrhythmias, tissue damage from extravasated CaCl 2.
    [Show full text]
  • Picture As Pdf Download
    NOTABLE CASES Succimer therapy for congenital lead poisoning from maternal petrol sniffing An infant, born at 35 weeks’ gestation to a woman who sniffed petrol, had a cord blood lead level eight times the accepted limit. Treatment with oral dimercaptosuccinic acid promptly reduced his blood lead levels. To our knowledge, this is the first reported case of congenital lead poisoning secondary to maternal petrol sniffing. We suggest that at-risk pregnancies should be identified, cord blood lead levels tested, and chelation therapy and developmental follow-up offered to affected infants. (MJA 2006; 184: 84-85) Clinical record therapy is recommended for any child with blood lead levels of μ 3 A 27-year-old Indigenous woman, who had sniffed petrol since 2.16 mol/L and over. Although chelation therapy in early child- childhood, presented for antenatal care during her first pregnancy. hood lowers blood levels, recent studies have not shown signifi- At the age of 14 years, she had severe lead encephalopathy that led cant improvement in cognitive and behavioural measurements 3,4,7 to chronic neurological deficits, including permanent ataxia and compared with untreated children. memory impairment. Her serum lead levels at 8 and 35 weeks’ There are a few case reports of neonatal lead intoxication that gestation were raised at 1.48 and 2.21 μmol/L, respectively (recom- occurred from maternal exposure to lead through pica, home 8-10 mended level, р 0.48 μmol/L1). renovation, or use of contaminated herbal medications. Petrol At 35 weeks’ gestation, she went into spontaneous labour and sniffing is a form of substance misuse that is widespread in some gave birth vaginally to a boy.
    [Show full text]
  • Oral Chelation Therapy for Patients with Lead Poisoning
    ORAL CHELATION THERAPY FOR PATIENTS WITH LEAD POISONING Jennifer A. Lowry, MD Division of Clinical Pharmacology and Medical Toxicology The Children’s Mercy Hospitals and Clinics Kansas City, MO 64108 Tel: (816) 234-3059 Fax: (816) 855-1958 December 2010 1 TABLE OF CONTENTS 1. Background of Lead Poisoning …………………………………………………………...3 a. Clinical Significance of Lead Measurements …………………………………….3 b. Absorption of Lead and Its Internal Distribution Within the Body ………………3 c. Toxic Effects of Exposure to Lead in Children and Adults ………………………4 d. Reproductive and Developmental Effects………………………………………...5 e. Mechanisms of Lead Toxicity ……………………………………………………6 f. Concentration of Lead in Blood Deemed Safe for Children/Adults………………6 g. Use of Blood Lead Measurements as a Marker of Lead Exposure ……………….7 2. Management of the Child with Elevated Blood Lead Concentrations …………………...8 a. Decreasing Exposure……………………………………………………………...8 b. Chelation Therapy…………………………………………………………………8 3. Oral Chelation Therapy …………………………………………………………………...8 a. Meso-2,3 dimercaptosuccinic acid (DMSA, Succimer) …………………………8 i. Pharmacokinetics………………………………………………………….9 ii. Dosing …………………………………………………………………….9 iii. Efficacy……………………………………………………………………9 iv. Safety…………………………………………………………………….11 b. Racemic-2,3-dimercapto-1-propanesulfonic acid (DMPS, Unithiol)……………11 i. Pharmacokinetics………………………………………………………...12 ii. Dosing ……………………………………………………………………12 iii. Efficacy…………………………………………………………………..12 iv. Safety…………………………………………………………………….12 c. Penicillamine……………………………………………………………………..12 i. Pharmacokinetics………………………………………………………...13
    [Show full text]